JPM, Free Full-Text
4.9 (340) In stock
The majority of breast cancers are oestrogen receptor-positive (ER+). In ER+ cancers, oestrogen acts as a disease driver, so these tumours are likely to be susceptible to endocrine therapy (ET). ET works by blocking the hormone’s synthesis or effect. A significant number of patients diagnosed with breast cancer will have the spread of tumour cells into regional lymph nodes either at the time of diagnosis, or as a recurrence some years later. Patients with node-positive disease have a poorer prognosis and can respond less well to ET. The nodal metastases may be genomically similar or, as is becoming more evident, may differ from the primary tumour. However, nodal metastatic disease is often not assessed, and treatment decisions are almost always based on biomarkers evaluated in the primary tumour. This review will summarise the evidence in the field on ER+, node-positive breast cancer, including diagnosis, treatment, prognosis and predictive tools.
JPM, Free Full-Text
Guide to Alternatives J.P. Morgan Asset Management
JPMorgan Chase Full Year 2023 Earnings: Misses Expectations
J.P. Morgan Podcasts
JPM & Sons Corp - Long Island, NY
JPM, Free Full-Text
JPM, Free Full-Text
Global Research
JPM, Free Full-Text
Who Was J.P. Morgan? How Did He Make a Fortune?
JPM, Free Full-Text
JPM, Free Full-Text
Chase Expands Retail Branches to All Lower 48 States
JPM, Free Full-Text, click desenvolvimento aec entrar
Jamie Dimon's Letter to Shareholders, Annual Report 2020
September is Blood Cancer Awareness Month
- ABC Classic-Fit Trouser 30L *Warpstreme, Men's Trousers
- Men's Majestic Threads Royal New York Giants Primary Logo Tri-Blend Hoodie T-Shirt
- CRZ YOGA Womens Fleece Lined Half Zip Hoodies Pullover Oversized
- Black Side White Piping High Waist Compression Leggings Winter Fitness Stacked Sport Women - AliExpress
- Bra Strap Padding, Medical Port Bra Strap Padding, Chemo Port, Heart, Scar Padding, Pacemaker Bra Padding, Seatbelt Padding
- Men's Striped Woven 2pk Boxer - Goodfellow & Co™ Navy : Target